News headlines about Fluidigm Corporation (NASDAQ:FLDM) have trended somewhat positive recently, Alpha One reports. The research group, a division of Accern, identifies negative and positive press coverage by monitoring more than twenty million blog and news sources. Alpha One ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Fluidigm Corporation earned a daily sentiment score of 0.16 on Alpha One’s scale. Alpha One also assigned media headlines about the medical research company an impact score of 78 out of 100, meaning that recent press coverage is likely to have an effect on the company’s share price in the near term.
A number of research analysts recently issued reports on FLDM shares. ValuEngine downgraded Fluidigm Corporation from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd. Zacks Investment Research raised Fluidigm Corporation from a “sell” rating to a “hold” rating in a research report on Thursday, June 1st.
Shares of Fluidigm Corporation (NASDAQ FLDM) traded up 3.01% during trading on Monday, reaching $3.77. The company had a trading volume of 162,640 shares. The stock’s 50-day moving average price is $4.89 and its 200-day moving average price is $5.94. The stock’s market capitalization is $110.44 million. Fluidigm Corporation has a 12 month low of $3.54 and a 12 month high of $10.94.
In other news, Director Samuel D. Colella purchased 7,500 shares of the firm’s stock in a transaction on Tuesday, May 9th. The stock was bought at an average cost of $5.93 per share, for a total transaction of $44,475.00. Following the completion of the acquisition, the director now directly owns 43,523 shares of the company’s stock, valued at $258,091.39. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Evan/ Fa Jones sold 10,900 shares of the company’s stock in a transaction dated Wednesday, June 7th. The shares were sold at an average price of $4.54, for a total transaction of $49,486.00. The disclosure for this sale can be found here. 4.50% of the stock is owned by corporate insiders.
ILLEGAL ACTIVITY NOTICE: “Fluidigm Corporation (FLDM) Receiving Somewhat Favorable Press Coverage, Analysis Finds” was first published by BBNS and is owned by of BBNS. If you are reading this report on another website, it was illegally copied and reposted in violation of United States and international trademark & copyright laws. The legal version of this report can be read at https://baseballnewssource.com/markets/fluidigm-corporation-fldm-earning-somewhat-favorable-media-coverage-report-finds-updated/985485.html.
About Fluidigm Corporation
Fluidigm Corporation creates, manufactures and markets technologies and life science tools focused on the exploration and analysis of single cells, as well as the industrial application of genomics, based upon the Company’s core microfluidics and mass cytometry technologies. The Company operates in the development, manufacturing and commercialization of life science tools for the life science and Ag-Bio industries segment.
Receive News & Ratings for Fluidigm Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fluidigm Corporation and related companies with our FREE daily email newsletter.